Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A.; Pagel, J.; Coombs, C.; Shah, N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T.; Woyach, J.; Wierda, W.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis - Update of clinical and translational data from the ongoing MANIFEST trial
    Meeting Abstract

    Curto-Garcia, N.; Kremyanskaya, M.; Mascarenhas, J.; Palandri, F.; Vannucchi, A. M.; Verstovsek, S.; Harrison, C.; Bose, P.; Schiller, G. J.; Rampal, R.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory follicular lymphoma who have received ≥ 2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Chaganti, S.; Cwynarski, K.; Cunningham, D.; Locke, F. L.; Miklos, D. B.; Jacobson, C. A.; Perales, M. A.; Kersten, M. J.; Oluwole, O. O.; Ghobadi, A.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukaemia: Final 5-year results from the BFORE trial
    Meeting Abstract

    Milojkovic, D.; Brümmendorf, T. H.; Cortes, J. E.; Gambacorti-Passerini, C.; Clark, R. E.; Le Coutre, P.; García-Gutierrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma: Results from the phase III POLARIX study
    Meeting Abstract

    Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Immune profile of gastric cancers with expression of programmed death receptor ligand-1
    Meeting Abstract

    Abate, M. E.; Lin, Y. H.; Strong, V.; Vardhana, S.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Current treatment of peripheral T-cell lymphoma
    Review

    Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Lewis, N.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.
    Oncology (Norwalk) (2022)

    Fulltext@MSK | Save
  • Predictors of adequacy and adverse events during spleen biopsy in oncologic patients
    Meeting Abstract

    Kunin, H.; Wijetunga, N.; Erinjeri, J.; Noy, A.; Deipolyi, A.
    Journal of Vascular and Interventional Radiology (2022)

    Fulltext@MSK | Save
  • PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome
    Journal Article

    Lewis, N. E.; Gao, Q.; Petrova-Drus, K.; Pulitzer, M.; Sigler, A.; Baik, J.; Moskowitz, A. J.; Horwitz, S. M.; Dogan, A.; Roshal, M.
    Cytometry Part B—Clinical Cytometry (2022)

    Fulltext@MSK | Save